

References

I-199

1. IlumyaTM [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc. Revised 8/2018.
2. MICROMEDEX[®]SOLUTIONS Compendia. 2019. Tildrakizumab.
3. Clinical Pharmacology Compendia. [database online]. 2019. Tampa FL: Gold Standard, Inc. Tildrakizumab.
4. Blauvelt A, Reich K, Papp K, et al. Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Three Randomized Controlled Trials. *Br J Dermatol*. 2018;179(3):615-622.
5. Menter A, Gottlieb A, Feldman S, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. *J Am Acad Dermatol*. 2018;58(5):826-850.
6. Menter A, Strober B, Kaplan D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80:1029-1072.